TRANSCEND-T2D-1 randomized 537 patients with type 2 diabetes and inadequate glycemic control in a 1:1:1:1 ratio to receive one of three retatrutide doses (4, 9, or 12 mg) or placebo
Not all patients qualify for the program
I could not independently verify them
This is an important treatment aspect, as weight reduction most likely plays an important role in the prevention and reduced progression of CKD, an association demonstrated in people with macroalbuminuria having undergone bariatric surgery [115]
First of all, apparently, it works in the reverse: GLP-1 receptor inhibition can result in weight loss (in mice), so, thats pretty weird
Comprising 39 amino acids with a C20 fatty diacid side chain for half-life extension, tirzepatide is designed for once-weekly subcutaneous injection